Shilpa Medicare informs about disclosure

19 Nov 2021 Evaluate
Shilpa Medicare has informed that US FDA has concluded Remote Record Review of Shilpa Medicare, Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th November 2021. Shilpa Medicare, Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

300.20 13.00 (4.53%)
03-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1702.80
Dr. Reddys Lab 1235.00
Cipla 1322.45
Zydus Lifesciences 902.95
Lupin 2186.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×